Lexaria Bioscience Corp. (LEXX)Healthcare | Biotechnology | Kelowna, Canada | NasdaqCM
0.99 USD
-0.04
(-3.505%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:50 p.m. EDT
Despite a technically strong recent bounce recovering from a significant dilutive $3.5M ATM offering, LEXX remains an aggressive long-term speculative hold with negative earnings, deteriorating fundamentals (-72.5% operating margins), and zero analyst support, making any upside purely reliant on FDA catalysts rather than value. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.091829 |
| AutoARIMA | 0.091829 |
| MSTL | 0.097344 |
| AutoTheta | 0.185812 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 3.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.009 |
| Excess Kurtosis | 0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.52 |
| Revenue per Share | 0.018 |
| Market Cap | 24,636,242 |
| Forward P/E | -2.55 |
| Beta | 0.48 |
| Previous Name | Lexaria Corp. |
| Website | https://lexariabioscience.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3191781 |
| Address1 | 740 McCurdy Road |
| Address2 | Suite 100 |
| All Time High | 12.5 |
| All Time Low | 0.46 |
| Ask | 1.05 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 181,760 |
| Average Daily Volume3 Month | 176,006 |
| Average Volume | 176,006 |
| Average Volume10Days | 181,760 |
| Beta | 0.478 |
| Bid | 0.9373 |
| Bid Size | 2 |
| Book Value | 0.265 |
| City | Kelowna |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.9939 |
| Current Ratio | 26.88 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.05 |
| Day Low | 0.9753 |
| Debt To Equity | 1.52 |
| Display Name | Lexaria Bioscience |
| Dividend Date | 1,610,409,600 |
| Earnings Timestamp End | 1,752,494,400 |
| Earnings Timestamp Start | 1,752,145,140 |
| Ebitda | -9,128,868 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.089 |
| Enterprise To Revenue | 51.818 |
| Enterprise Value | 19,069,030 |
| Eps Forward | -0.39 |
| Eps Trailing Twelve Months | -0.47 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.77898 |
| Fifty Day Average Change | 0.21491998 |
| Fifty Day Average Change Percent | 0.27589923 |
| Fifty Two Week Change Percent | -31.91781 |
| Fifty Two Week High | 1.69 |
| Fifty Two Week High Change | -0.69610006 |
| Fifty Two Week High Change Percent | -0.41189352 |
| Fifty Two Week Low | 0.46 |
| Fifty Two Week Low Change | 0.5339 |
| Fifty Two Week Low Change Percent | 1.1606522 |
| Fifty Two Week Range | 0.46 - 1.69 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,610,461,800,000 |
| Float Shares | 23,438,761 |
| Forward Eps | -0.39 |
| Forward P E | -2.5484617 |
| Free Cashflow | -5,925,560 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 368,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05741 |
| Held Percent Institutions | 0.06441 |
| Implied Shares Outstanding | 24,787,446 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,756,598,400 |
| Long Business Summary | Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. |
| Long Name | Lexaria Bioscience Corp. |
| Market | us_market |
| Market Cap | 24,636,242 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_26180395 |
| Most Recent Quarter | 1,772,236,800 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -9,529,916 |
| Next Fiscal Year End | 1,788,134,400 |
| Non Diluted Market Cap | 24,636,242 |
| Number Of Analyst Opinions | 2 |
| Open | 1.05 |
| Operating Cashflow | -9,374,421 |
| Operating Margins | -72.59515 |
| Payout Ratio | 0.0 |
| Phone | 250 765 6424 |
| Pre Market Change | -0.034200013 |
| Pre Market Change Percent | -3.4409914 |
| Pre Market Price | 0.9597 |
| Pre Market Time | 1,776,775,827 |
| Prev Name | Lexaria Corp. |
| Previous Close | 1.03 |
| Price Hint | 4 |
| Price To Book | 3.7505662 |
| Price To Sales Trailing12 Months | 66.94631 |
| Profit Margins | 0.0 |
| Quick Ratio | 24.742 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0361 |
| Regular Market Change Percent | -3.50485 |
| Regular Market Day High | 1.05 |
| Regular Market Day Low | 0.9753 |
| Regular Market Day Range | 0.9753 - 1.05 |
| Regular Market Open | 1.05 |
| Regular Market Previous Close | 1.03 |
| Regular Market Price | 0.9939 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 189,780 |
| Return On Assets | -0.75975 |
| Return On Equity | -1.47067 |
| Revenue Growth | -0.885 |
| Revenue Per Share | 0.018 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 24,787,446 |
| Shares Percent Shares Out | 0.0114 |
| Shares Short | 283,017 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 383,896 |
| Short Name | Lexaria Bioscience Corp. |
| Short Percent Of Float | 0.0117999995 |
| Short Ratio | 1.82 |
| Source Interval | 15 |
| State | BC |
| Symbol | LEXX |
| Target High Price | 6.0 |
| Target Low Price | 1.5 |
| Target Mean Price | 3.75 |
| Target Median Price | 3.75 |
| Total Cash | 5,269,407 |
| Total Cash Per Share | 0.213 |
| Total Debt | 94,386 |
| Total Revenue | 368,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.88924 |
| Two Hundred Day Average Change | 0.104659975 |
| Two Hundred Day Average Change Percent | 0.11769598 |
| Type Disp | Equity |
| Volume | 189,780 |
| Website | https://lexariabioscience.com |
| Zip | V1X 2P7 |